Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMQM2FH)

Drug Name

RRx-001 Drug Info

Synonyms

RRX-001; 925206-65-1; 2-BROMO-1-(3,3-DINITROAZETIDIN-1-YL)ETHAN-1-ONE; UNII-7RPW6SU9SC; 2-Bromo-1-(3,3-dinitroazetidin-1-yl)ethanone; 7RPW6SU9SC; RRx001; Ethanone, 2-bromo-1-(3,3-dinitro-1-azetidinyl)-; SCHEMBL2249018; CHEMBL3526802; MolPort-044-559-098; EX-A2006; BCP19228; 1-bromoacetyl-3,3-dinitroazetidine; ZINC34805177; s8405; DB12060; CS-5286; HY-16438; AS-53015

Indication

Disease Entry	ICD 11	Status	REF
Small-cell lung cancer	2C25.Y	Phase 3	[1]
Lymphoma	2A80-2A86	Phase 2	[2]
Neuroendocrine cancer	2B72.1	Phase 2	[3]
Non-small-cell lung cancer	2C25.Y	Phase 2	[3]
Ovarian epithelial cancer	2C73	Phase 2	[3]
Anaplastic glioma	2A00.0	Phase 1	[3]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[3]

Cross-matching ID

PubChem CID: 15950826
CAS Number: CAS 925206-65-1
TTD Drug ID: DMQM2FH

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Free radical (FRD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Disufenton sodium	DMJS8V3	Ischemia	8B10-8B11	Phase 3	[5]
SM-88	DMD9ISG	Pancreatic cancer	2C10	Phase 2/3	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Free radical (FRD)	TT8E7Z0	NOUNIPROTAC	Modulator	[4]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT03699956) RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung Cancer (REPLATINUM). U.S. National Institutes of Health.
2	ClinicalTrials.gov (NCT02452970) RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials. Cancer Res. 2012 May 15;72(10):2600-8.
5	NXY-059, a free radical--trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species. Stroke. 2001 Jan;32(1):190-8.